The DRD2 gene (rs1799978, TT) is correlated with good response to risperidone treatment; and the ANKK1/DRD2 (rs1800497, GG) is correlated with reduced risk for hyperprolactinemia and weight gain but increased possibility for tardive dyskinesia. This evidence concerns the gene DRD2 and hyperprolactinemia.